


## EU Declaration of Conformity


We hereby declare under our sole responsibility that the Primus system meets the relevant provisions of the following European Union Directives:

- Council **Directive 93/42/EEC** of 14 June 1993 concerning medical devices as amended by Directive 2007/47/EC (**MDD**)
- **Directive 2006/42/EC** of the European Parliament and of the Council of 17 May 2006 on machinery as amended by Regulation (EU) 2019/1243
- **Directive 2011/65/EU** of the European Parliament and of the Council of 8 June 2011 on the restriction of the use of certain hazardous substances in electrical and electronic equipment (**RoHS**)

The Primus has undergone a conformity assessment procedure required by the MDD and is manufactured in harmony with the Technical Documentation compiled as defined in the relevant Directives and retained by BTE.

Product information in regard to the **MDD** and **RoHS** Directives:

<b>Manufacturer</b> 	BTE Technologies 7455-L New Ridge Road Hanover, MD 21076, USA <a href="http://www.btetechnologies.com">www.btetechnologies.com</a>	Telephone: 410.850.0333 Email: <a href="mailto:Service@btetechnologies.com">Service@btetechnologies.com</a>
<b>Product Identification</b>	<b>Device Trade Name:</b> PrimusRS <b>Device Name:</b> Primus <b>Model:</b> PrimusRS (PRRS)	
<b>UDI-DI</b>	10850390007243	
<b>EMDN (CND) code</b>	Z120616 - PHYSICAL THERAPY AND REHABILITATION SYSTEMS	
<b>Intended Purpose</b>	The Primus is intended to be used for musculoskeletal strength testing and exercise. Applications include physical rehabilitation and sports therapy. The system is intended to measure strength, increase muscle strength and endurance, and track patient progress through the process. It may be used for upper extremity, lower extremity, and trunk muscle weakness.	
<b>Device Classification (MDD)</b>	Class I	
<b>Classification Rule (MDD)</b>	Rule 12	

<b>Route to Compliance (MDD)</b>	Annex VII of the Medical Devices Directive
<b>Device Classification (MDR)</b>	Class IIa
<b>Classification Rule (MDR)</b>	Rule 11
<b>CE Marking Provision</b>	<p>Under <b>Medical Device Regulation (EU) 2017/745 (MDR)</b>, the device will be up-classified to class IIa due to changed software classification rules. Based on the MDR Article 120 §3, the PRIMUS can be placed on the EU market as a class I device until May 26, 2024 provided that the device</p> <ul style="list-style-type: none"> <li>• will continue to comply with the MDD,</li> <li>• there will be no significant changes in the design and intended purpose, and</li> <li>• the device will comply with the MDR requirements for post market surveillance, vigilance, and registration of economic operators and of devices</li> </ul>
<b>Authorized Representative</b> 	<p>Emergo Europe  Prinsessegracht 20  2514 AP, The Hague  The Netherlands</p> <p>Telephone: +31.70.345.8570  Emails: <a href="mailto:EmergoEurope@ul.com">EmergoEurope@ul.com</a>  <a href="mailto:EmergoVigilance@ul.com">EmergoVigilance@ul.com</a></p>

The device is CE marked since 2004.

Signed for on behalf of BTE Technologies



Ewa Kaczanowska  
PRRC/Regulatory Manager  
BTE Technologies

Hanover, MD

May 20, 2021



The Technology of Human Performance

## Addendum to the original Declaration of Conformity

Per 31 January 2023, the address of our EU Authorized Representative as listed on the original DoC has changed.

OLD ADDRESS AUTHORIZED REPRESENTATIVE		
Name of company	Address	Telephone/email
Emergo Europe	Prinsessegracht 20 2514 AP The Hague The Netherlands	+31.70.345.8570 - phone EmergoEurope@ul.com

NEW ADDRESS AUTHORIZED REPRESENTATIVE		
Name of company	Address	Telephone/email
Emergo Europe	Westervoortsedijk 60 6827 AT Arnhem The Netherlands	+31.70.345.8570 - phone EmergoEurope@ul.com

COMPANY REPRESENTATIVE:

Ewa Kaczanowska  
Regulatory Manager/PRRC

June 2, 2023